-
CCHIO 2025 | Professor Zhu Jun: Breaking Barriers and Shaping Momentum — A New Blueprint for CAR-T in China Driven by Policy, Payment, and Innovation
From November 6 to 9, 2025, the China Conference on Holistic and Integrative Oncology (CCHIO 2025) was successfully held in Kunming. As one of the largest and most influential oncology…
-
CCHIO Chair Speaks | Professor Zhang Huilai: Integrative and Precision Oncology in Lymphoma — Practice, Progress, and Future Directions
From November 6 to 9, 2025, the China Conference on Holistic and Integrative Oncology (CCHIO 2025) was successfully held in the spring city of Kunming. As one of the largest…
-
Prof. Jiye Liu: Monoclonal Antibody Therapy for Multiple Myeloma—Current Status, Resistance Mechanisms, and Subsequent Strategies
丨 2025 International Cell & Immunotherapy Congress** To promote innovation in China’s cell and immunotherapy fields, deepen scientific exchange, share the latest clinical research progress, and foster global collaboration and…
-
Prof. Chunrui Li: The Leap from Target Innovation to Clinical Breakthroughs in CAR-T Therapy for Multiple Myeloma
To promote innovation in China’s cell and immunotherapy landscape, facilitate in-depth exchange on key scientific questions, share the latest clinical research progress, and strengthen global collaboration and clinical translation, the 2025 International Cell & Immunotherapy Congress (CTI 2025)—jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), the Zhejiang Society of Immunology, and…
-
Professor He Huang: Uniting Global Strength to Lead the Frontier丨2025 International Cell and Immunotherapy Congress
To advance innovation in China’s cell therapy and immunotherapy landscape, deepen discussion on key scientific questions, share the latest clinical research progress, and promote global collaboration and clinical translation within the field, the 2025 International Cell and Immunotherapy Congress (CTI 2025) was held in Hangzhou, Zhejiang, from November 13 to 16, 2025. The congress was…
-
ASH China Voice丨Zunmin Zhu / Mingfeng Zhao / Wenyi Lu: IL-18 and RQR8 Suicide-Switch Dual-Armored CLL-1 CAR-T Cells Enhance the Efficacy and Safety of AML Therapy
The 67th American Society of Hematology (ASH) Annual Meeting will be held from December 6 to 9, 2025, in Orlando, USA. As one of the largest, most influential, and most comprehensive international congresses in hematology, ASH attracts tens of thousands of experts and scholars from around the world each year to share the latest advances…
-
Professor Ye Xiongjun: From Systemic Therapy to Minimally Invasive Surgery — What “Surprises” Await in Kidney Cancer Treatment?
In recent years, the incidence of urological malignancies in China has risen steadily. Prostate, bladder, and kidney cancers now rank among the most common malignancies in the country, posing a serious threat to public health. The Department of Urology at the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS), has long…
-
Precision Targeted Therapy for Bladder Cancer Reaches a New Milestone: Professor Xu Tao’s Team from Peking University People’s Hospital Demonstrates Potent Synergistic Effects Through Combination Treatment
Bladder cancer is one of the most common malignant tumors of the genitourinary system. In recent years, the emergence of antibody-drug conjugates (ADCs) has brought new hope for patients with advanced bladder cancer. Among them, Enfortumab Vedotin (EV) — an ADC targeting the tumor antigen Nectin-4 — has been hailed as a “precision-guided missile.” However,…
Connecting Medical Expertise through Media